Ingevity/$NGVT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ingevity

Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.

Ticker

$NGVT
Sector

Primary listing

NYSE

Industry

Chemicals

Employees

1,600

ISIN

US45688C1071

Ingevity Metrics

BasicAdvanced
$1.6B
-
-$9.74
1.39
-

What the Analysts think about Ingevity

Analyst ratings (Buy, Hold, Sell) for Ingevity stock.

Bulls say / Bears say

Ingevity's Performance Materials division achieved record performance in 2024, with margins exceeding 50%, driven by new pricing and operational efficiency initiatives. (stocktitan.net)
The company announced a strategic review of its Industrial Specialties product line and North Charleston CTO refinery, aiming to enhance profitability and shareholder value. (stocktitan.net)
Ingevity's Performance Chemicals segment transformation delivered $84 million in savings in 2024, surpassing their $65-75 million target, with additional savings of $10-25 million expected in 2025. (stocktitan.net)
Ingevity's Q1 2025 revenues fell 16.5% year over year to $284 million, primarily due to lower sales in the Industrial Specialties product line and the Advanced Polymer Technologies segment. (nasdaq.com)
The company reported a net loss of $283.7 million in Q2 2024, compared to a profit of $35.5 million in the year-ago quarter, indicating significant financial challenges. (nasdaq.com)
Ingevity's stock has declined approximately 38% over the past three years, underperforming the market and raising concerns about its long-term growth prospects. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.

Ingevity Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Ingevity Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NGVT

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs